In an article from the Telegraph it noted that the Royal College of Psychiatrists is to review its opposition to the legalisation of cannabis a critical move since much of the research the government has used to keep cannabis as an illegal drug has been conducted by leading researchers from the College.
Geremy Thomas, founder and CEO of Sativa Investments, the UK’s first medicinal cannabis investment vehicle, said:
“The Royal College of Psychiatrists is another welcome addition to the list of medical bodies in the UK who are reviewing the opposition to legalising medicinal cannabis, including The Royal College of Physicians, British Medical Journal, British Medical Association and Royal Society for Public Health who have called for reform to current laws.
“With this number of experts in the field stating that we need reform, it is surely time for the government to get moving and catch up with the rest of the other markets who are already ahead of the curve. The UK could be one of the leaders in this rapidly growing market, now is the time to move forward.”
Sativa Investments (NEX:SATI) seeks to invest in global companies which are well-placed to take advantage of the dynamic regulatory environment surrounding medical Cannabis. It’s investment strategy focuses on production, pharmacology, testing and compliance, R&D commercialisation, and sales and marketing.